methylphenidate has been researched along with Idiopathic Parkinson Disease in 43 studies
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty Parkinson's disease (PD) patients, 6 patients with essential tremor and 10 healthy controls were studied with the dopamine transporter ligand [(11)C]d-threo-methylphenidate ([(11)C]dMP) and positron emission tomography (PET) to assess dopamine terminal loss in relation to disease duration and motor disability." | 9.12 | [(11)C]d-threo-methylphenidate PET in patients with Parkinson's disease and essential tremor. ( Breit, S; Klockgether, T; Reimold, M; Reischl, G; Wüllner, U, 2006) |
| "Fatigue is a common nonmotor symptom in idiopathic Parkinson disease (IPD) that can prominently affect everyday function." | 6.73 | Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial. ( Jog, MS; Mendonça, DA; Menezes, K, 2007) |
| "Twenty Parkinson's disease (PD) patients, 6 patients with essential tremor and 10 healthy controls were studied with the dopamine transporter ligand [(11)C]d-threo-methylphenidate ([(11)C]dMP) and positron emission tomography (PET) to assess dopamine terminal loss in relation to disease duration and motor disability." | 5.12 | [(11)C]d-threo-methylphenidate PET in patients with Parkinson's disease and essential tremor. ( Breit, S; Klockgether, T; Reimold, M; Reischl, G; Wüllner, U, 2006) |
| "To determine if repeated dosing with methylphenidate hydrochloride (MPD) (Ritalin; Novartis Pharmaceuticals, East Hanover, NJ), an inhibitor of the dopamine transporter, would augment the effects of oral levodopa in patients with Parkinson disease." | 5.12 | Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial. ( Carlson, NE; Carter, JH; Nutt, JG, 2007) |
| "Methylphenidate improved gait hypokinesia and freezing in patients with advanced Parkinson's disease receiving subthalamic nucleus stimulation." | 2.77 | Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. ( Azulay, JP; Bloem, BR; Bordet, R; Brefel-Courbon, C; Corvol, JC; Debû, B; Defebvre, L; Delval, A; Destée, A; Devos, D; Drapier, S; Duhamel, A; Dujardin, K; Durif, F; Eusebio, A; Faighel, M; Fraix, V; Giordana, C; Guehl, D; Houeto, JL; Lagha-Boukbiza, O; Maltête, D; Moreau, C; Ory-Magne, F; Petyt, G; Rascol, O; Sablonniere, B; Saulnier, PJ; Tison, F; Tranchant, C; Vidailhet, M; Vuillaume, I, 2012) |
| "Sustained drug therapy in Parkinson's disease may alter the psychomotor responses to acute challenges with dopaminergic drugs, L-dopa and methylphenidate, and cause cross sensitisation." | 2.74 | Changes in psychomotor effects of L-dopa and methylphenidate after sustained dopaminergic therapy in Parkinson's disease. ( Evans, AH; Lawrence, AD; Lees, AJ, 2009) |
| "Fatigue is a common nonmotor symptom in idiopathic Parkinson disease (IPD) that can prominently affect everyday function." | 2.73 | Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial. ( Jog, MS; Mendonça, DA; Menezes, K, 2007) |
| "The importance of DAT in Parkinson's disease (PD) in which DAT may be reduced by 50 to 70% is unclear." | 2.71 | The dopamine transporter: importance in Parkinson's disease. ( Carter, JH; Nutt, JG; Sexton, GJ, 2004) |
| "Brains of patients with Parkinson's disease show depletion of ventral tegmental area mesolimbic-mesocortical neurons." | 2.69 | Parkinsonian patients report blunted subjective effects of methylphenidate. ( Henningfield, JE; Kuhar, MJ; Persico, AM; Reich, S; Uhl, GR, 1998) |
| "Methylphenidate is a CNS stimulant that blocks the DaT and the noradrenaline (norepinephrine) transporter in the striatum and the prefrontal cortex in particular." | 1.39 | Methylphenidate : a treatment for Parkinson's disease? ( Bordet, R; Defebvre, L; Delval, A; Devos, D; Dujardin, K; Moreau, C, 2013) |
| "Twenty-seven of the 36 patients had dyskinesias." | 1.35 | PET demonstrates reduced dopamine transporter expression in PD with dyskinesias. ( de la Fuente-Fernandez, R; Mak, E; Ruth, TJ; Schulzer, M; Sossi, V; Stoessl, AJ; Troiano, AR, 2009) |
| "Five men with advanced idiopathic Parkinson's disease (PD) were examined to assess the effect of low dose methylphenidate (MPD) on gait." | 1.34 | Low dose methylphenidate improves freezing in advanced Parkinson's disease during off-state. ( Bahunker, S; Dobronevsky, Y; Pollak, L; Prohorov, T; Rabey, JM, 2007) |
| "Methylphenidate (MPH) is a centrally acting (psycho)stimulant which reversibly blocks the dopamine re-uptake transporter." | 1.34 | Association of Parkinson's disease with symptoms of attention deficit hyperactivity disorder in childhood. ( Gerlach, M; Herhaus, G; Lange, KW; Melfsen, S; Müller, T; Scheuerpflug, P; Walitza, S; Warnke, A, 2007) |
| "The causes of nigrostriatal neuron degeneration in Parkinson's disease (PD) are not known, but it has been suggested that exogenous or endogenous factors or neurotoxins may play a role." | 1.33 | An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate. ( Delville, Y; Fleming, SM; Schallert, T, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (9.30) | 18.7374 |
| 1990's | 4 (9.30) | 18.2507 |
| 2000's | 18 (41.86) | 29.6817 |
| 2010's | 15 (34.88) | 24.3611 |
| 2020's | 2 (4.65) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, JF | 3 |
| Wegener, T | 3 |
| Klyuzhin, IS | 3 |
| Mannheim, JG | 3 |
| McKeown, MJ | 3 |
| Stoessl, AJ | 9 |
| Sossi, V | 9 |
| Faustini, G | 1 |
| Longhena, F | 1 |
| Bruno, A | 1 |
| Bono, F | 1 |
| Grigoletto, J | 1 |
| La Via, L | 1 |
| Barbon, A | 1 |
| Casiraghi, A | 1 |
| Straniero, V | 1 |
| Valoti, E | 1 |
| Costantino, G | 1 |
| Benfenati, F | 1 |
| Missale, C | 1 |
| Pizzi, M | 1 |
| Spillantini, MG | 1 |
| Bellucci, A | 1 |
| Huynh, KN | 1 |
| Nguyen, BD | 1 |
| Mancera, N | 1 |
| Wadia, HP | 1 |
| Devos, D | 5 |
| Moreau, C | 4 |
| Dujardin, K | 5 |
| Cabantchik, I | 1 |
| Defebvre, L | 5 |
| Bordet, R | 4 |
| Cheng, G | 1 |
| Morley, JF | 1 |
| Delval, A | 3 |
| Bleuse, S | 1 |
| Guehl, D | 2 |
| Bestaven, E | 1 |
| Guillaud, E | 1 |
| Schneider, JS | 1 |
| Cambi, F | 1 |
| Gollomp, SM | 1 |
| Kuwabara, H | 1 |
| Brašić, JR | 1 |
| Leiby, B | 1 |
| Sendek, S | 1 |
| Wong, DF | 1 |
| Lotze, M | 1 |
| Reimold, M | 2 |
| Heymans, U | 1 |
| Laihinen, A | 1 |
| Patt, M | 1 |
| Halsband, U | 1 |
| Evans, AH | 1 |
| Lawrence, AD | 1 |
| Lees, AJ | 1 |
| Troiano, AR | 1 |
| de la Fuente-Fernandez, R | 4 |
| Schulzer, M | 4 |
| Mak, E | 3 |
| Ruth, TJ | 5 |
| Hausdorff, JM | 1 |
| Kuramoto, L | 1 |
| Cragg, J | 1 |
| Ramachandiran, N | 1 |
| Au, WL | 1 |
| McKenzie, J | 2 |
| McCormick, S | 1 |
| Lee, CS | 3 |
| Calne, DB | 3 |
| Espay, AJ | 1 |
| Dwivedi, AK | 1 |
| Payne, M | 1 |
| Gaines, L | 1 |
| Vaughan, JE | 1 |
| Maddux, BN | 1 |
| Slevin, JT | 1 |
| Gartner, M | 1 |
| Sahay, A | 1 |
| Revilla, FJ | 1 |
| Duker, AP | 1 |
| Shukla, R | 1 |
| Shi, M | 1 |
| Furay, AR | 1 |
| Aasly, JO | 1 |
| Armaly, J | 1 |
| Wang, Y | 1 |
| Wszolek, ZK | 2 |
| Uitti, RJ | 2 |
| Hasegawa, K | 1 |
| Yokoyama, T | 1 |
| Zabetian, CP | 1 |
| Leverenz, JB | 1 |
| Zhang, J | 1 |
| Foley, PB | 1 |
| Dinelle, K | 1 |
| Jivan, S | 1 |
| Fischer, K | 1 |
| Holden, JE | 1 |
| Doudet, D | 1 |
| Duhamel, A | 2 |
| Petyt, G | 1 |
| Vuillaume, I | 1 |
| Corvol, JC | 1 |
| Brefel-Courbon, C | 1 |
| Ory-Magne, F | 1 |
| Eusebio, A | 1 |
| Fraix, V | 1 |
| Saulnier, PJ | 1 |
| Lagha-Boukbiza, O | 1 |
| Durif, F | 1 |
| Faighel, M | 1 |
| Giordana, C | 1 |
| Drapier, S | 1 |
| Maltête, D | 1 |
| Tranchant, C | 1 |
| Houeto, JL | 1 |
| Debû, B | 1 |
| Sablonniere, B | 1 |
| Azulay, JP | 1 |
| Tison, F | 1 |
| Rascol, O | 1 |
| Vidailhet, M | 1 |
| Destée, A | 2 |
| Bloem, BR | 1 |
| Rodriguez-Oroz, MC | 1 |
| Drijgers, RL | 1 |
| Verhey, FR | 1 |
| Tissingh, G | 1 |
| van Domburg, PH | 1 |
| Aalten, P | 1 |
| Leentjens, AF | 1 |
| Hwang, JJ | 1 |
| Liao, MH | 1 |
| Yen, TC | 1 |
| Wey, SP | 1 |
| Lin, KJ | 1 |
| Pan, WH | 1 |
| Chen, JC | 1 |
| Ting, G | 1 |
| Chatterjee, A | 1 |
| Fahn, S | 1 |
| Furtado, S | 1 |
| Guttman, M | 1 |
| Furukawa, Y | 1 |
| GIBERTI, F | 1 |
| GIANNIOTTI, G | 1 |
| SPIZZIRRI, S | 1 |
| Nutt, JG | 2 |
| Carter, JH | 2 |
| Sexton, GJ | 1 |
| Fleming, SM | 1 |
| Delville, Y | 1 |
| Schallert, T | 1 |
| Breit, S | 1 |
| Reischl, G | 1 |
| Klockgether, T | 1 |
| Wüllner, U | 1 |
| Adams, JR | 1 |
| van Netten, H | 1 |
| Strongosky, A | 1 |
| Farrer, M | 1 |
| Gasser, T | 1 |
| Koochesfahani, KM | 1 |
| Yatham, LN | 1 |
| Blinder, S | 1 |
| Alisky, JM | 1 |
| Krystkowiak, P | 1 |
| Clement, F | 1 |
| Cottencin, O | 1 |
| Waucquier, N | 1 |
| Ajebbar, K | 1 |
| Thielemans, B | 1 |
| Kroumova, M | 1 |
| Carlson, NE | 1 |
| Mendonça, DA | 1 |
| Menezes, K | 1 |
| Jog, MS | 1 |
| Pollak, L | 1 |
| Dobronevsky, Y | 1 |
| Prohorov, T | 1 |
| Bahunker, S | 1 |
| Rabey, JM | 1 |
| Walitza, S | 1 |
| Melfsen, S | 1 |
| Herhaus, G | 1 |
| Scheuerpflug, P | 1 |
| Warnke, A | 1 |
| Müller, T | 1 |
| Lange, KW | 1 |
| Gerlach, M | 1 |
| Ding, YS | 2 |
| Fowler, JS | 2 |
| Volkow, ND | 2 |
| Gatley, SJ | 2 |
| Logan, J | 1 |
| Dewey, SL | 1 |
| Alexoff, D | 1 |
| Fazzini, E | 1 |
| Wolf, AP | 1 |
| Wang, GJ | 1 |
| Persico, AM | 1 |
| Reich, S | 1 |
| Henningfield, JE | 1 |
| Kuhar, MJ | 1 |
| Uhl, GR | 1 |
| Seeman, P | 1 |
| Madras, BK | 1 |
| Cantello, R | 2 |
| Aguggia, M | 2 |
| Gilli, M | 2 |
| Delsedime, M | 2 |
| Riccio, A | 2 |
| Rainero, I | 1 |
| Mutani, R | 2 |
| Chiardò Cutin, I | 1 |
| Miller, E | 1 |
| Nieburg, HA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Rhythmic Auditory Stimulation Optimalization for Gait Improvement in Parkinson's[NCT02438124] | 80 participants (Anticipated) | Interventional | 2014-09-30 | Recruiting | |||
| Methylphenidate for the Treatment of Gain Impairment in Parkinson's Disease: a Randomized Double-Blind, Placebo-Controlled, Cross-over Study[NCT00526630] | Phase 4 | 23 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease: A Single Center, Randomized Pilot Study[NCT02879136] | Early Phase 1 | 42 participants (Anticipated) | Interventional | 2016-12-31 | Recruiting | ||
| Study of Methylphenidate to Treat Gait Disorders And Attention Deficit In Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentric Trial[NCT00914095] | Phase 4 | 69 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| The Role of a Personalized Music Intervention Towards Alleviating Apathy in Parkinson's Disease[NCT05505019] | 50 participants (Anticipated) | Interventional | 2022-02-09 | Recruiting | |||
| Subacute Trial of Methylphenidate in Parkinson's Disease[NCT00359723] | Phase 2 | 13 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
| Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism[NCT03446807] | Phase 2 | 0 participants (Actual) | Interventional | 2021-12-31 | Withdrawn (stopped due to Sponsor Decision to terminate) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
FOGQ is a questionnaire that quantifies severity of gait and falls. It contains 16 items with a 0-4 severity scale for each, for a range of 0 (normal) to 64 (most severe impairment). (NCT00526630)
Timeframe: Week 12 and 27
| Intervention | units on a scale (Mean) |
|---|---|
| 1. MPD | 12.31 |
| 2. Placebo | 12.56 |
| Baseline | 12.71 |
MADRS is a questionnaire used to measure the severity of depressive episodes in patients with mood disorders. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60 (NCT00526630)
Timeframe: Week 12 and 27
| Intervention | units on a scale (Mean) |
|---|---|
| 1. MPD | 5.79 |
| 2. Placebo | 6.71 |
| Baseline | 9.44 |
The EQ-5D comprises five questions on mobility, self care, pain, usual activities, and psychological status with three possible answers for each item (1=no problem, 2=moderate problem, 3=severe problem; see appendix). A summary index with a maximum score of 1 can be derived from these five dimensions by conversion with a table of scores. The range is from 0 to 100, with 100 indicating the best health status. (NCT00526630)
Timeframe: Week 12 and 27
| Intervention | units on a scale (Mean) |
|---|---|
| 1. MPD | 65 |
| 2. Placebo | 63.94 |
| Baseline | 68.67 |
The Epworth Sleepiness Scale (ESS) is a scale intended to measure daytime sleepiness that is measured by use of a very short questionnaire. The questionnaire asks the subject to rate his or her probability of falling asleep on a scale of increasing probability from 0 to 3 for eight different situations that most people engage in during their daily lives, though not necessarily every day. The scores for the eight questions are added together to obtain a single number. A number in the 0-9 range is considered to be normal while a number in the 10-24 range indicates excessive daytime sleepiness. Higher scores imply worse sleepiness. (NCT00526630)
Timeframe: Week 12 and 27
| Intervention | units on a scale (Mean) |
|---|---|
| 1. MPD | 11.05 |
| 2. Placebo | 10.71 |
| Baseline | 11.24 |
"Gait stride length is the distance between two consecutive steps in the on state. This will be measured by the GAITRite System, which is an electronic walkway utilized to measure the temporal (timing) and spatial (two dimension geometric position) parameters of its pressure activated sensors." (NCT00526630)
Timeframe: Week 12 and 27
| Intervention | centimeters (Mean) |
|---|---|
| 1. MPD | 107.66 |
| 2. Placebo | 112.29 |
| Baseline | 103.35 |
"Gait velocity is a measure of distance over time in the on state. This will be measured by the GAITRite System, which is an electronic walkway utilized to measure the temporal (timing) and spatial (two dimension geometric position) parameters of its pressure activated sensors." (NCT00526630)
Timeframe: Week 12 and 27
| Intervention | centimeters/second (Mean) |
|---|---|
| 1. MPD | 96.96 |
| 2. Placebo | 99.24 |
| Baseline | 95.76 |
Patients will have a mild to severe gait disturbance with score >1 on the motor subscale of the Unified Parkinson's disease rating scale (UPDRS) but without need for a continuous ambulatory aid such as walker or wheelchair (Hoehn & Yahr 2-3). The highest score possible for the UPDRS is 108 which indicates severe motor impairment. The lowest score for the UPDRS is 0 which indicates no motor impairment. (NCT00526630)
Timeframe: At week 12 and 27
| Intervention | units on a scale (Mean) |
|---|---|
| 1. MPD | 21.18 |
| 2. Placebo | 20.33 |
| Baseline | 18.39 |
Freezing and shuffling are measures of ambulatory impairment. (NCT00526630)
Timeframe: Week 12 and 27
| Intervention | hours (Mean) | |
|---|---|---|
| Shuffling | Freezing | |
| 1. MPD | 7.67 | 3.07 |
| 2. Placebo | 6.15 | 3.25 |
| Baseline | 9.1 | 5.4 |
3 reviews available for methylphenidate and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
New pharmacological options for treating advanced Parkinson's disease.
Topics: Apathy; Cholinesterase Inhibitors; Clinical Trials as Topic; Deep Brain Stimulation; Dopamine Plasma | 2013 |
Gait dynamics in Parkinson's disease: common and distinct behavior among stride length, gait variability, and fractal-like scaling.
Topics: Acoustic Stimulation; Biomechanical Phenomena; Biophysical Phenomena; Case-Control Studies; Central | 2009 |
Anti-hyperactivity medication: methylphenidate and amphetamine.
Topics: Adult; Amino Acid Sequence; Amphetamine; Animals; Attention Deficit Disorder with Hyperactivity; Cen | 1998 |
17 trials available for methylphenidate and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Gait and attentional performance in freezers under methylphenidate.
Topics: Aged; Attention; Dopamine Uptake Inhibitors; Female; Gait Disorders, Neurologic; Humans; Male; Methy | 2015 |
GM1 ganglioside in Parkinson's disease: Pilot study of effects on dopamine transporter binding.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbon Isotopes; Corpus Striatum; Dopamine Pla | 2015 |
Reduced ventrolateral fMRI response during observation of emotional gestures related to the degree of dopaminergic impairment in Parkinson disease.
Topics: Aged; Brain; Brain Mapping; Carbon Radioisotopes; Case-Control Studies; Corpus Striatum; Dopamine; D | 2009 |
Changes in psychomotor effects of L-dopa and methylphenidate after sustained dopaminergic therapy in Parkinson's disease.
Topics: Adult; Affect; Aged; Antiparkinson Agents; Central Nervous System Stimulants; Dopamine Agents; Doubl | 2009 |
Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Gait Disorders, Neurologic; Humans; Mal | 2011 |
Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Gait Disorders, Neurologic; Humans; Mal | 2011 |
Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Gait Disorders, Neurologic; Humans; Mal | 2011 |
Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Gait Disorders, Neurologic; Humans; Mal | 2011 |
Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial.
Topics: Female; Gait Disorders, Neurologic; Humans; Male; Methylphenidate; Parkinson Disease | 2011 |
Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial.
Topics: Aged; Deep Brain Stimulation; Dopamine Uptake Inhibitors; Double-Blind Method; Female; France; Gait | 2012 |
The role of the dopaminergic system in mood, motivation and cognition in Parkinson's disease: a double blind randomized placebo-controlled experimental challenge with pramipexole and methylphenidate.
Topics: Affect; Aged; Benzothiazoles; Cognition; Dopamine Agonists; Dopamine Uptake Inhibitors; Dopaminergic | 2012 |
The dopamine transporter: importance in Parkinson's disease.
Topics: Aged; Analysis of Variance; Blood Pressure; Dopamine Agents; Dopamine Plasma Membrane Transport Prot | 2004 |
[(11)C]d-threo-methylphenidate PET in patients with Parkinson's disease and essential tremor.
Topics: Aged; Carbon Radioisotopes; Disability Evaluation; Dopamine Plasma Membrane Transport Proteins; Esse | 2006 |
Oral methylphenidate fails to elicit significant changes in extracellular putaminal dopamine levels in Parkinson's disease patients: positron emission tomographic studies.
Topics: Administration, Oral; Adult; Aged; Basal Ganglia; Caudate Nucleus; Central Nervous System Stimulants | 2006 |
Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease.
Topics: Aged; Central Nervous System Stimulants; Dose-Response Relationship, Drug; Fatigue; Female; Gait Dis | 2007 |
Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease.
Topics: Aged; Central Nervous System Stimulants; Dose-Response Relationship, Drug; Fatigue; Female; Gait Dis | 2007 |
Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease.
Topics: Aged; Central Nervous System Stimulants; Dose-Response Relationship, Drug; Fatigue; Female; Gait Dis | 2007 |
Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease.
Topics: Aged; Central Nervous System Stimulants; Dose-Response Relationship, Drug; Fatigue; Female; Gait Dis | 2007 |
Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Cross-Over Studies; Dopamine Uptake Inhibitors; Do | 2007 |
Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial.
Topics: Aged; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female; Humans; Male; Methylp | 2007 |
Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial.
Topics: Aged; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female; Humans; Male; Methylp | 2007 |
Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial.
Topics: Aged; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female; Humans; Male; Methylp | 2007 |
Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial.
Topics: Aged; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female; Humans; Male; Methylp | 2007 |
Parkinsonian patients report blunted subjective effects of methylphenidate.
Topics: Adult; Affect; Aged; Depressive Disorder; Dopamine Uptake Inhibitors; Dose-Response Relationship, Dr | 1998 |
Analgesic action of methylphenidate on parkinsonian sensory symptoms. Mechanisms and pathophysiological implications.
Topics: Aged; Analgesics; Biogenic Amines; Biomechanical Phenomena; Humans; Male; Methylphenidate; Methyserg | 1988 |
Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: possible role of the "hedonic" dopamine synapse.
Topics: Adult; Aged; Arousal; Clinical Trials as Topic; Depressive Disorder; Double-Blind Method; Euphoria; | 1989 |
23 other studies available for methylphenidate and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Spatiotemporal patterns of putaminal dopamine processing in Parkinson's disease: A multi-tracer positron emission tomography study.
Topics: Cross-Sectional Studies; Dopamine; Dopamine Plasma Membrane Transport Proteins; Humans; Levodopa; Me | 2022 |
Spatiotemporal patterns of putaminal dopamine processing in Parkinson's disease: A multi-tracer positron emission tomography study.
Topics: Cross-Sectional Studies; Dopamine; Dopamine Plasma Membrane Transport Proteins; Humans; Levodopa; Me | 2022 |
Spatiotemporal patterns of putaminal dopamine processing in Parkinson's disease: A multi-tracer positron emission tomography study.
Topics: Cross-Sectional Studies; Dopamine; Dopamine Plasma Membrane Transport Proteins; Humans; Levodopa; Me | 2022 |
Spatiotemporal patterns of putaminal dopamine processing in Parkinson's disease: A multi-tracer positron emission tomography study.
Topics: Cross-Sectional Studies; Dopamine; Dopamine Plasma Membrane Transport Proteins; Humans; Levodopa; Me | 2022 |
Alpha-synuclein/synapsin III pathological interplay boosts the motor response to methylphenidate.
Topics: alpha-Synuclein; Animals; Cocaine; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transport Pro | 2020 |
False-Positive DaTscan Features With Methylphenidate and Phentermine Therapy.
Topics: Adult; Contraindications, Drug; Dopamine Uptake Inhibitors; Dopaminergic Neurons; False Positive Rea | 2018 |
Corneal Edema Associated With Systemic Dopaminergic Agents.
Topics: Adult; Aged; Attention Deficit Disorder with Hyperactivity; Corneal Edema; Diterpenes; Dopamine; Dop | 2019 |
Complete and readily reversible blocking of striatal DaTscan binding by methylphenidate.
Topics: Aged, 80 and over; Humans; Male; Methylphenidate; Neostriatum; Nortropanes; Parkinson Disease; Radio | 2014 |
PET demonstrates reduced dopamine transporter expression in PD with dyskinesias.
Topics: Caudate Nucleus; Dopamine Plasma Membrane Transport Proteins; Dyskinesias; Female; Humans; Logistic | 2009 |
Age-specific progression of nigrostriatal dysfunction in Parkinson's disease.
Topics: Adult; Aged; Aging; Carbon Isotopes; Corpus Striatum; Disease Progression; Female; Fluorodeoxyglucos | 2011 |
DJ-1 and αSYN in LRRK2 CSF do not correlate with striatal dopaminergic function.
Topics: alpha-Synuclein; Biomarkers; Carbon Isotopes; Corpus Striatum; Dopamine; Female; Fluorodeoxyglucose | 2012 |
In vivo dopamine transporter imaging in a unilateral 6-hydroxydopamine rat model of Parkinson disease using 11C-methylphenidate PET.
Topics: Animals; Carbon Radioisotopes; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; | 2012 |
Methylphenidate for freezing of gait in Parkinson's disease.
Topics: Deep Brain Stimulation; Dopamine Uptake Inhibitors; Female; Gait Disorders, Neurologic; Humans; Hypo | 2012 |
Methylphenidate : a treatment for Parkinson's disease?
Topics: Animals; Antiparkinson Agents; Central Nervous System Stimulants; Corpus Striatum; Dopamine; Dopamin | 2013 |
Biodistribution study of [99mTc] TRODAT-1 alone or combined with other dopaminergic drugs in mice with macroautoradiography.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Brain; Cocaine; Dopamine Age | 2002 |
Methylphenidate treats apathy in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Central Nervous System Stimulants; Humans; Male; Methylphenidate; Parkinson | 2002 |
VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET.
Topics: Adolescent; Adult; Carbon Radioisotopes; Corpus Striatum; Cytoplasmic Vesicles; Dopamine; Dopamine A | 2003 |
[Further results of new therapy of Parkinsonian syndromes; therapeutic action of 3-phenyl-3-b-diethylamino-ethyl-2-6-dioxy-piperidine hydrochloride administered alone and with reserpine and ritalin].
Topics: Methylphenidate; Parasympatholytics; Parkinson Disease; Parkinsonian Disorders; Piperidines; Reserpi | 1957 |
An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Carbidopa; Cell Count; Differential Threshold; Dise | 2005 |
PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation.
Topics: Adult; Age Factors; Aged; Brain; Carbon Radioisotopes; Carboxy-Lyases; Case-Control Studies; Dopamin | 2005 |
A new approach to Parkinson's disease combining caffeine, methylphenidate, and anticholinergic agents: case histories, pharmacological data, and a conceptual framework from traditional Chinese medicine.
Topics: Adult; Aged; Antiparkinson Agents; Caffeine; Disorders of Excessive Somnolence; Drug Therapy, Combin | 2006 |
Low dose methylphenidate improves freezing in advanced Parkinson's disease during off-state.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Dopamine Plasma Membrane Transport Proteins; Dopamine | 2007 |
Association of Parkinson's disease with symptoms of attention deficit hyperactivity disorder in childhood.
Topics: Adult; Aged; Aged, 80 and over; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; | 2007 |
Pharmacokinetics and in vivo specificity of [11C]dl-threo-methylphenidate for the presynaptic dopaminergic neuron.
Topics: Aged; Animals; Chromatography, High Pressure Liquid; Dopamine; Dopamine Uptake Inhibitors; Female; H | 1994 |
Positron emission tomography radioligands for dopamine transporters and studies in human and nonhuman primates.
Topics: Animals; Brain; Carbon Radioisotopes; Carrier Proteins; Cocaine; Dopamine; Dopamine Plasma Membrane | 1998 |
Amphetamines, valuable adjunct in treatment of Parkinsonism.
Topics: Aged; Amphetamine; Dextroamphetamine; Dihydroxyphenylalanine; Humans; Methylphenidate; Parkinson Dis | 1973 |